Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, a clinical-stage biopharmaceutical company developing a novel class of tumor targeted therapies for initial application in primary tumors such as choroidal melanoma, today announced the dosing of the first patient in a Phase 2 study evaluating the safety and efficacy of suprachoroidal (SC) administration of AU-011, the Company’s lead product candidate, as a potential first-line treatment for patients with primary choroidal melanoma. “I am hon

Full Story →